Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
US Court Approves airBaltic Chapter 11 Restructuring 
Najib Razak Seeks Stay of 15-Year 1MDB Prison Sentence 
Soybean Futures Slip as Traders Await Trump-Xi Trade Signals 
Najib Razak Granted House Arrest Until 2028 
Fed’s Hammack Says Bond Yield Surge Is Not Driven by Inflation Fears 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP 
Appeals Court Rejects Trump Third-Country Deportation Policy 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Apple Extends Qualcomm Patent Licensing Deal 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Add as a preferred source on Google
Abbott Laboratories faces a criminal investigation by the Justice Department, after its recall of formulas due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The Justice Department was investigating conduct at Abbott’s plant in Sturgis, Michigan,
According to an Abbott spokesman, they are fully cooperating with the Justice Department without specifying what aspect of the company is under scrutiny.
In February 2022, Abbott, the biggest US supplier of baby formula, recalled Similac and other infant formula products produced at its Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The US Food and Drug Administration found "shocking" results during an inspection, such as cracks in vital equipment, inadequate hand-washing, and evidence of previous bacterial contamination.
The plant has since reopened.
